Kenvue Inc. (KVUE) Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal quarter and six months ended June 30, 2024. Kenvue Inc. is a global consumer health company operating in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company became fully independent from Johnson & Johnson (J&J) in August 2023 following an exchange offer and a subsequent debt-for-equity exchange in May 2024, leaving J&J with no remaining ownership stake.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Net Sales | $4.000 billion | $4.011 billion | $7.894 billion | $7.863 billion |
| Gross Profit | $2.365 billion | $2.225 billion | $4.607 billion | $4.350 billion |
| Gross Margin | 59.1% | 55.5% | 58.4% | 55.3% |
| Operating Income | $154 million | $702 million | $704 million | $1.342 billion |
| Net Income | $58 million | $430 million | $354 million | $899 million |
| Diluted EPS | $0.03 | $0.23 | $0.18 | $0.51 |
| Operating Cash Flow (YTD) | $727 million (vs. $1.544 billion YTD 2023) | |||
| Total Debt | $8.478 billion (as of June 30, 2024) | |||
| Cash & Equivalents | $1.014 billion (as of June 30, 2024) |
Material Changes vs. Prior Period
- Impairment Charges: Net income and operating income were significantly impacted by $510 million in impairment charges for Q2 2024 ($578 million YTD). This includes a $488 million non-cash charge related to the Dr.Ci:Labo brand in China due to strategic shifts and market dynamics, and a $68 million charge for the interim corporate headquarters in Skillman, NJ, classified as held for sale.
- Restructuring: The company initiated a "2024 Multi-Year Restructuring Initiative" in May 2024, incurring $48 million in restructuring expenses for Q2 ($89 million YTD). The initiative targets approximately $550 million in total pre-tax charges over 2024 and 2025.
- Segment Performance:
- Essential Health: Strongest performer with 4.9% sales growth in Q2, driven by Oral Care and Women's Health.
- Skin Health and Beauty: Sales declined 3.8% in Q2, primarily due to volume decreases in the U.S. and China.
- Self Care: Sales declined 1.6% in Q2, impacted by lower cold/flu incidences and trade inventory fluctuations.
- Cost of Sales: Decreased 8.5% in Q2 due to supply chain optimization benefits and favorable currency impacts, contributing to a 360 basis point expansion in gross margin.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects the 2024 Multi-Year Restructuring Initiative to result in approximately $275 million in pre-tax expenses in each of fiscal years 2024 and 2025. Benefits are expected to be reinvested in growth opportunities.
- Dividends: The Board declared a quarterly dividend of $0.205 per share (a 2.5% increase), payable August 28, 2024.
- Share Repurchases: The company repurchased 4.6 million shares for $91 million in the first half of 2024 under a program authorized to offset dilution from equity awards.
- Legal Contingencies: Significant ongoing litigation includes:
- Talc: J&J retains liabilities for U.S. and Canada; Kenvue retains liabilities for international markets.
- Acetaminophen (Tylenol): Multi-district litigation regarding autism/ADHD claims; recent court judgments in favor of the company, though appeals are pending.
- Phenylephrine (PE): Class actions alleging ineffectiveness following an FDA advisory committee vote.
- Benzene: Litigation regarding sunscreen and acne products.
- Deferred Markets: Certain assets and liabilities in jurisdictions like China, Malaysia, and Russia were deferred from the J&J separation and remain subject to transfer timing and regulatory approvals.
Investor Verification Checklist
- Dr.Ci:Labo Strategy: Verify the specifics of the new strategic plan for the Dr.Ci:Labo brand in China and the assumptions used in the revised cash flow forecasts that triggered the $488 million impairment.
- Restructuring Execution: Monitor the pace of the $550 million restructuring initiative and the realization of expected cost savings versus the incurred charges.
- Legal Exposure: Assess the potential financial impact of the pending appeals in the acetaminophen litigation and the status of the benzene and phenylephrine class actions.
- Deferred Local Businesses: Track the progress of transferring assets and liabilities from J&J for the Deferred Local Businesses, particularly in China and Russia, to ensure full consolidation and operational control.
- Volume Trends: Analyze the sustainability of volume declines in the Skin Health and Beauty and Self Care segments versus the growth in Essential Health.